EXEL - Exelixis Teva fight over Cabometyx generic again

• Cancer-focused biotech Exelixis, Inc. ( NASDAQ: EXEL ) has filed another court case against Israeli drugmaker Teva Pharmaceutical Industries ( TEVA ) on allegations of patent infringement related to a generic version of the company’s kidney cancer therapy Cabometyx.
• The lawsuit filed in the District Court in Delaware asserts infringement of U.S. Patent No. 11,298,349 due to an amendment in TEVA’s marketing application for a generic version of Cabometyx, EXEL said in a regulatory filing.
• With the amendment for the Abbreviated New Drug Application, TEVA seeks to market its generic drug before the 2032 expiry of the patent.
• Considered a standard of care for renal cell carcinoma, Cabometyx added more than $1B in net product revenue for EXEL in 2021.
• Two companies are engaged in a separate patent infringement case involving certain other Cabometyx patents, the latest of which expires in Jul. 2033.

For further details see: